PMID- 18848768
OWN - NLM
STAT- MEDLINE
DCOM- 20091203
LR  - 20151119
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 63
IP  - 7
DP  - 2009 Aug
TI  - Soluble TNFR II/IgG1 Fc fusion protein treatment in the LPS-mediated septic shock 
      of rats.
PG  - 537-42
LID - 10.1016/j.biopha.2008.08.012 [doi]
AB  - Tumor necrosis factor-alpha (TNF-alpha) is thought to play a major role in 
      systemic inflammation associated with sepsis. A potent TNF antagonist, a 
      recombinant fusion protein that consists of the soluble TNF receptor (p75) linked 
      to the Fc portion of human IgG1 (sTNFR II/IgG1 Fc fusion protein, sTNFR:Fc), has 
      been shown to provide rapid and sustained improvement in local inflammation 
      diseases by binding TNF-alpha and preventing its proinflammatory activities. To 
      explore the potential therapeutic efficacy for septic shock of sTNFR:Fc, we 
      investigate the effect of this molecule on the survival rate, blood pressure, 
      serum TNF-alpha bioactivity as well as the expression of TNF-alpha at mRNA level 
      in the liver in a LPS-induced rat septic shock model. Blood pressure of the rats 
      was monitored by multi-channel creature signal analysis system. Serum TNF-alpha 
      level and bioactivity was assessed using an enzyme-linked immunoassay and a L929 
      cytotoxicity assay, respectively. The expression of TNF-alpha mRNA in liver was 
      examined by semi-quantitative RT-PCR. sTNFR:Fc administered to rats 24h before 
      LPS challenge ablated the rise in serum TNF-alpha bioactivity that occurs in 
      response to LPS and protected against hypotension and death. These results 
      indicate that TNF-alpha is a mediator of fatal septic shock, and suggest that 
      sTNFR:Fc offer a potential therapy of systemic infection.
FAU - Guo, Zhuying
AU  - Guo Z
AD  - Experimental Center, No. 3 People's Hospital Affiliated to Shanghai Jiao Tong 
      University School of Medicine, No. 280, Baoshan District, Shanghai 201900, China. 
      zyguoo@126.com
FAU - Wang, Shiting
AU  - Wang S
FAU - Jiao, Qiang
AU  - Jiao Q
FAU - Xu, Manghua
AU  - Xu M
FAU - Xu, Zhimei
AU  - Xu Z
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080916
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunologic Factors)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Animals
MH  - Blood Pressure/drug effects
MH  - Etanercept
MH  - Humans
MH  - Immunoglobulin G/*therapeutic use
MH  - Immunologic Factors/*therapeutic use
MH  - Lipopolysaccharides/pharmacology
MH  - Liver/metabolism
MH  - RNA, Messenger/biosynthesis
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Tumor Necrosis Factor/*therapeutic use
MH  - Shock, Septic/*drug therapy/mortality/physiopathology
MH  - Survival Rate
MH  - Tumor Necrosis Factor-alpha/biosynthesis/blood/genetics
EDAT- 2008/10/14 09:00
MHDA- 2009/12/16 06:00
CRDT- 2008/10/14 09:00
PHST- 2008/07/16 00:00 [received]
PHST- 2008/08/24 00:00 [accepted]
PHST- 2008/10/14 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
PHST- 2008/10/14 09:00 [entrez]
AID - S0753-3322(08)00300-4 [pii]
AID - 10.1016/j.biopha.2008.08.012 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2009 Aug;63(7):537-42. doi: 10.1016/j.biopha.2008.08.012. 
      Epub 2008 Sep 16.